{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:17:10Z","timestamp":1762647430015,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018529","name":"Alkermes Plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.dadr.2025.100346","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T02:41:11Z","timestamp":1747363271000},"page":"100346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploring the impact of a medication adherence intervention on recovery and mental health outcomes: A secondary analysis of the MAT-PLUS pilot RCT"],"prefix":"10.1016","volume":"15","author":[{"given":"Kevin","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Carrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Stidham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2025.100346_bib1","first-page":"0030","article-title":"2022 National Healthcare Quality and Disparities Report. Rockville, MD","volume":"22","author":"Agency for Healthcare Research and Quality","year":"2022"},{"issue":"4","key":"10.1016\/j.dadr.2025.100346_bib2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/add.15732","article-title":"The science of recovery capital: where do we go from here?","volume":"117","author":"Best","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100346_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.109875","article-title":"Development and psychometric properties of the Multidimensional Inventory of Recovery Capital (MIRC)","volume":"247","author":"Bowen","year":"2023","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.dadr.2025.100346_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/16066359.2014.938061","article-title":"Psychometric properties of the recovery assessment scale in a sample with substance use disorder","volume":"23","author":"Cale","year":"2014","journal-title":"Addict. Res. Theory"},{"issue":"7","key":"10.1016\/j.dadr.2025.100346_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1360-0443.2011.03400.x","article-title":"Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial","volume":"106","author":"Everly","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.dadr.2025.100346_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108076","article-title":"A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder","volume":"117","author":"Farabee","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.dadr.2025.100346_bib7","article-title":"Recovery Assessment Scale (RAS)","author":"Giffort","year":"1995","journal-title":"APA PsycTests"},{"issue":"3","key":"10.1016\/j.dadr.2025.100346_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40429-018-0215-x","article-title":"Medication treatments for opioid use disorder: what is the impact on mood and mood disorders?","volume":"5","author":"Hassan","year":"2018","journal-title":"Curr. Addict. Rep."},{"issue":"7","key":"10.1016\/j.dadr.2025.100346_bib9","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.dadr.2025.100346_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s11414-017-9563-x","article-title":"Factor structure and sensitivity to change of the recovery assessment scale","volume":"45","author":"Jones","year":"2018","journal-title":"J. Behav. Health Serv. Res"},{"issue":"4","key":"10.1016\/j.dadr.2025.100346_bib11","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.mcna.2016.03.011","article-title":"Pharmacotherapy for substance use disorders","volume":"100","author":"Klein","year":"2016","journal-title":"Med. Clin. North Am."},{"issue":"4","key":"10.1016\/j.dadr.2025.100346_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.genhosppsych.2010.03.006","article-title":"The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review","volume":"32","author":"Kroenke","year":"2010","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.dadr.2025.100346_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.05.031","article-title":"Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: a systematic review and meta-analysis","volume":"154","author":"Lai","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.dadr.2025.100346_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00952990600918973","article-title":"Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?","volume":"32","author":"Nunes","year":"2006","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"1","key":"10.1016\/j.dadr.2025.100346_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12954-021-00553-w","article-title":"Recovery capital among people receiving treatment for opioid use disorder with buprenorphine","volume":"18","author":"Parlier-Ahmad","year":"2021","journal-title":"Harm Reduct. J."},{"issue":"2","key":"10.1016\/j.dadr.2025.100346_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","author":"Sullivan","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.dadr.2025.100346_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ajad.13371","article-title":"Trajectories of depression among patients in treatment for opioid use disorder: a growth mixture model secondary analysis of the XBOT trial","volume":"32","author":"Vest","year":"2023","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.dadr.2025.100346_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2017.03.022","article-title":"Development and validation of a Brief Assessment of Recovery Capital (BARC-10) for alcohol and drug use disorder","volume":"177","author":"Vilsaint","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.dadr.2025.100346_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.15288\/jsad.2019.80.572","article-title":"Adherence across FDA-approved medications for alcohol use disorder in a veterans administration population","volume":"80","author":"Walker","year":"2019","journal-title":"J. Stud. Alcohol Drugs"},{"issue":"4","key":"10.1016\/j.dadr.2025.100346_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.chc.2024.02.007","article-title":"An assertive community intervention to engage youth with opioid use disorder and their families","volume":"33","author":"Wenzel","year":"2024","journal-title":"Child Adolesc. Psychiatr. Clin. North Am."},{"key":"10.1016\/j.dadr.2025.100346_bib21","article-title":"A pilot randomized controlled trial of medication adherence therapy: psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone","volume":"163","author":"Wenzel","year":"2024","journal-title":"J. Subst. Use Addict. Treat."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724625000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:12:45Z","timestamp":1762647165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724625000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"alternative-id":["S2772724625000290"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100346","relation":{},"ISSN":["2772-7246"],"issn-type":[{"type":"print","value":"2772-7246"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the impact of a medication adherence intervention on recovery and mental health outcomes: A secondary analysis of the MAT-PLUS pilot RCT","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2025.100346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100346"}}